Recognizing the extraordinary resilience and courage of children and families fighting neuroblastoma and supports the incredible effort of clinicians and researchers working to address this disease and expressing support for September 3, 2026, to be designated as "Neuroblastoma Awareness Day".

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 1509 Introduced in House (IH)]

<DOC>

119th CONGRESS
  2d Session
H. RES. 1509

 Recognizing the extraordinary resilience and courage of children and 
 families fighting neuroblastoma and supports the incredible effort of 
    clinicians and researchers working to address this disease and 
     expressing support for September 3, 2026, to be designated as 
                    ``Neuroblastoma Awareness Day''.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                           September 3, 2026

   Ms. Chu (for herself and Mr. Kelly of Pennsylvania) submitted the 
following resolution; which was referred to the Committee on Oversight 
                         and Government Reform

_______________________________________________________________________

                               RESOLUTION

 
 Recognizing the extraordinary resilience and courage of children and 
 families fighting neuroblastoma and supports the incredible effort of 
    clinicians and researchers working to address this disease and 
     expressing support for September 3, 2026, to be designated as 
                    ``Neuroblastoma Awareness Day''.

Whereas neuroblastoma is the most common cancer in infants and the most common 
        extracranial solid tumor in childhood;
Whereas there are approximately 600 to 800 new cases of neuroblastoma diagnosed 
        each year in the United States;
Whereas neuroblastoma accounts for about 8 to 10 percent of all childhood 
        cancers and approximately 15 percent of childhood cancer deaths;
Whereas approximately 90 percent of neuroblastoma cases are diagnosed before 5 
        years of age, with many cases occurring during infancy;
Whereas symptoms are often nonspecific, which can delay diagnosis and treatment;
Whereas neuroblastoma accounts for a disproportionate share of pediatric cancer 
        deaths relative to its incidence;
Whereas high-risk neuroblastoma remains one of the most difficult pediatric 
        cancers to treat successfully;
Whereas the estimated 5-year survival rate for children with high-risk 
        neuroblastoma is approximately 63 percent;
Whereas treatment for high-risk neuroblastoma typically requires intensive 
        multimodal therapy, including chemotherapy, surgery, radiation therapy, 
        stem cell transplant, and immunotherapy;
Whereas survivors may experience significant lifelong health complications, 
        including hearing loss, organ failure, and subsequent malignancies;
Whereas children with neuroblastoma often require prolonged treatment and 
        repeated hospitalizations;
Whereas anti-GD2 immunotherapy has improved outcomes for children with high-risk 
        neuroblastoma;
Whereas emerging therapies, including CAR-T cell treatments targeting tumor 
        antigens such as B7-H3, are under active investigation for relapsed 
        disease;
Whereas childhood cancers, including neuroblastoma, historically receive 
        significantly less research funding compared to adulthood cancers;
Whereas children with high-risk or relapsed neuroblastoma continue to face 
        limited effective treatment options and a high risk of relapse, 
        highlighting the need for continued research and therapeutic 
        development;
Whereas increased awareness can support earlier diagnosis, improve outcomes, and 
        help drive investment in research and treatment advancements for 
        pediatric cancers;
Whereas September is recognized as Childhood Cancer Awareness Month in the 
        United States; and
Whereas the House of Representatives supports designating September 3, 2026, as 
        ``Neuroblastoma Awareness Day'': Now, therefore, be it
    Resolved, That the House of Representatives supports the 
designation of a ``Neuroblastoma Awareness Day'' to provide a dedicated 
opportunity to recognize the extraordinary resilience and courage of 
children and families fighting this disease and support the incredible 
effort of clinicians and researchers working to address this disease.
                                 <all>